David Cella

Jun 3, 2024 | brnw.ch | Bryan Schneider |Sofía García |David Cella

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Sep 15, 2023 | brnw.ch | Markus Moehler |Steven Blum |Elena Elimova |David Cella

Gastric/gastroesophageal junction cancer (GC/GEJC) and esophageal adenocarcinoma (EAC) are among the leading causes of global cancer-related mortality.1 Strong similarities in molecular profiles between GC/GEJC and EAC suggest that these cancers could be considered a single disease entity.2,3 Chemotherapy, the standard first-line treatment for patients with unresectable advanced or metastatic human epidermal growth factor receptor 2 (HER2)–negative GC/GEJC, has been associated with poor...